erythromycin 2'-acetate has been researched along with erythromycin in 26 studies
| Studies (erythromycin 2'-acetate) | Trials (erythromycin 2'-acetate) | Recent Studies (post-2010) (erythromycin 2'-acetate) | Studies (erythromycin) | Trials (erythromycin) | Recent Studies (post-2010) (erythromycin) |
|---|---|---|---|---|---|
| 27 | 14 | 0 | 14,524 | 1,138 | 1,926 |
| Protein | Taxonomy | erythromycin 2'-acetate (IC50) | erythromycin (IC50) |
|---|---|---|---|
| 30S ribosomal protein S6 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S7 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L15 | Escherichia coli K-12 | 1.156 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.045 | |
| 50S ribosomal protein L10 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L11 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L19 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L1 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L20 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L27 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L28 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L29 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L31 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L32 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L33 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L34 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L35 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L36 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S10 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S11 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S12 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S13 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S16 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S18 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S19 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S20 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S2 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S3 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S4 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S5 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S8 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S9 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L13 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L14 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L16 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L23 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S15 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L17 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L21 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L30 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L6 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S14 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S17 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S1 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L18 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L2 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L3 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L24 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L4 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L22 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L5 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S21 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L25 | Escherichia coli K-12 | 1.156 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.039 | |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | 1.156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (57.69) | 18.7374 |
| 1990's | 10 (38.46) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haataja, H; Järvinen, A; Mattila, J; Nykänen, S | 1 |
| Marvola, M; Nokelainen, M; Nykänen, S | 1 |
| Lankinen, KS; Lehtonen, L; Rita, H; Salmi, HA; Valtonen, V; Wikberg, R | 1 |
| Gordin, A; Kokkonen, P; Lehtinen, R; Peltola, J; Pohto, P; Tuominen, RK; Wikberg, R | 1 |
| Anttila, M; Laakso, S; Scheinin, M | 1 |
| Gordin, A; Kaukoranta-Tolvanen, SS; Männistö, PT; Renkonen, OV; Tamm, L | 1 |
| Hanhijärvi, H; Havas, A; Komulainen, H; Männistö, PT; Rauramaa, V; Vuorela, A | 1 |
| Allonen, H; Elonen, E; Roos, L; Saloranta, P | 1 |
| Korkeala, H; Männistö, PT | 1 |
| Antikainen, R; Gordin, A; Kokkonen, P; Männistö, PT; Rauramaa, V; Savolainen, S; Ylikoski, J | 1 |
| Antikainen, R; Brandt, H; Gordin, A; Salo, OP | 1 |
| Flygare, U; Hildén, M; Hurme, J; Järvinen, H; Leskinen, J; Pynnönen, S; Riikonen, A; Salomaa, V; Seuri, M; Wuolijoki, E | 1 |
| Antikainen, R; Gordin, A; Rostila, T; Visa, K | 1 |
| Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A | 1 |
| Haataja, H; Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A | 1 |
| Haataja, H; Kokkonen, P | 1 |
| Antikainen, R; Gordin, A; Haataja, H; Männistö, PT; Savolainen, S; Tuominen, RK; Ylikoski, J | 1 |
| Antikainen, R; Gordin, A; Hulmi, S; Kalima, S; Mäkelä, P | 1 |
| Collan, Y; Hanhijärvi, H; Husband, RF; Kosma, VM; Männistö, PT; Viluksela, M | 1 |
| Antikainen, R; Gordin, A; Salmi, HA | 1 |
| Lehtonen, L; Wiesner, B; Wilen-Rosenqvist, G | 1 |
| Karhunen, M; Kokkonen, P; Lehtonen, L; Tuominen, R; Wikberg, R | 1 |
| Kiesvaara, J; Niskanen, T; Riippi, M; Yliruusi, J | 1 |
| Antikainen, O; Niskanen, T; Riippi, M; Yliruusi, J | 1 |
| Järvinen, T; Niemi, R; Rautio, J | 1 |
| Riippi, M; Tanninen, V; Yliruusi, J | 1 |
13 trial(s) available for erythromycin 2'-acetate and erythromycin
| Article | Year |
|---|---|
Effect of food on absorption and hydrolysis of erythromycin acistrate.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Erythromycin; Female; Food; Humans; Hydrolysis; Intestinal Absorption; Male; Tablets, Enteric-Coated | 1992 |
Hepatic safety of erythromycin acistrate in 1549 patients with respiratory tract or skin infections.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Eating; Erythromycin; Female; gamma-Glutamyltransferase; Humans; Liver; Male; Middle Aged; Prodrugs; Respiratory Tract Infections; Skin Diseases, Infectious; Time Factors | 1991 |
Effect of erythromycin acistrate and erythromycin stearate on human colonic microflora.
Topics: Adolescent; Adult; Bacteria, Anaerobic; Colon; Erythromycin; Feces; Gram-Negative Bacteria; Humans; Random Allocation | 1989 |
Erythromycin ethylsuccinate, base and acistrate in the treatment of upper respiratory tract infection: two comparative studies of tolerability.
Topics: Adolescent; Adult; Aged; Erythromycin; Erythromycin Ethylsuccinate; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Respiratory Tract Infections | 1989 |
Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Dermatitis, Atopic; Double-Blind Method; Erythromycin; Female; Humans; Male; Middle Aged; Ointments; Prodrugs; Random Allocation; Skin Diseases, Infectious; Staphylococcal Skin Infections | 1988 |
Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Erythromycin; Female; Humans; Liver; Male; Middle Aged; Random Allocation; Respiratory Tract Infections; Tablets, Enteric-Coated | 1988 |
Erythromycin acistrate and erythromycin stearate in the treatment of non-gonococcal urethritis.
Topics: Adolescent; Adult; Chlamydia Infections; Erythromycin; Humans; Male; Prodrugs; Tetracycline; Urethritis | 1988 |
Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state.
Topics: Adult; Cimetidine; Drug Interactions; Erythromycin; Fasting; Female; Food; Humans; Intestinal Absorption; Male; Random Allocation; Tablets; Tablets, Enteric-Coated | 1988 |
Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base.
Topics: Adult; Blister; Erythromycin; Female; Humans; Hydrolysis; Male; Orosomucoid; Random Allocation; Saliva; Suction | 1988 |
Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis.
Topics: Adolescent; Adult; Chronic Disease; Erythromycin; Female; Humans; Hydrolysis; Male; Palatine Tonsil; Premedication; Prodrugs; Random Allocation; Tablets, Enteric-Coated; Tonsillitis | 1988 |
Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections.
Topics: Acute Disease; Adolescent; Adult; Double-Blind Method; Erythromycin; Female; Humans; Liver; Male; Middle Aged; Prodrugs; Random Allocation; Respiratory Tract Infections; Tablets, Enteric-Coated | 1988 |
Erythromycin acistrate and enterocoated pellets of erythromycin base in acute respiratory infections of hospitalized conscripts.
Topics: Acute Disease; Adolescent; Adult; Erythromycin; Hospitalization; Humans; Liver; Prodrugs; Random Allocation; Respiratory Tract Infections; Streptococcal Infections; Tablets, Enteric-Coated; Virus Diseases | 1988 |
Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia.
Topics: Acute Disease; Adult; Aged; Bronchitis; Double-Blind Method; Doxycycline; Erythromycin; Female; Humans; Male; Middle Aged; Pneumonia, Pneumococcal; Prodrugs; Respiratory Tract Infections | 1993 |
13 other study(ies) available for erythromycin 2'-acetate and erythromycin
| Article | Year |
|---|---|
Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.
Topics: Adult; Bicarbonates; Biological Availability; Capsules; Erythromycin; Female; Humans; Prodrugs; Sodium; Sodium Bicarbonate | 1991 |
Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: a pilot study.
Topics: Adult; Aged; Biological Availability; Erythromycin; Humans; Middle Aged; Periapical Granuloma; Pilot Projects; Premedication; Prodrugs; Radicular Cyst; Sepsis | 1991 |
Determination of erythromycin base and 2'-acetylerythromycin in human plasma using high-performance liquid chromatography with electrochemical detection.
Topics: Biological Availability; Chromatography, High Pressure Liquid; Drug Stability; Electrodes; Erythromycin; Humans; Hydrogen-Ion Concentration; Oleandomycin; Oxidation-Reduction; Reproducibility of Results; Temperature | 1990 |
Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice.
Topics: Animals; Erythromycin; Mice; Peritonitis; Staphylococcal Infections; Streptococcal Infections; Structure-Activity Relationship | 1989 |
Time course of the antibacterial activity of erythromycin stearate and erythromycin acistrate against two Staphylococcus aureus strains in vitro.
Topics: Drug Resistance, Microbial; Erythromycin; Prodrugs; Staphylococcus aureus; Time Factors | 1988 |
Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate.
Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythromycin; Female; Humans; Hydrolysis; Male; Palatine Tonsil | 1988 |
Determination of 2'-acetyl erythromycin and erythromycin in human tonsil tissue by HPLC with coulometric detection.
Topics: Chromatography, High Pressure Liquid; Electrochemistry; Erythromycin; Humans; Palatine Tonsil; Prodrugs | 1988 |
Comparative liver toxicity of various erythromycin derivatives in animals.
Topics: Animals; Body Weight; Cholangitis; Dogs; Dose-Response Relationship, Drug; Erythromycin; Esters; Female; Liver; Male; Organ Size; Random Allocation; Rats; Rats, Inbred Strains | 1988 |
Erythromycin and 2'-acetyl erythromycin concentrations in plasma and pelvic tissues after repeated doses of erythromycin acistrate.
Topics: Biotransformation; Endometrium; Erythromycin; Fallopian Tubes; Female; Humans; Hydrolysis; Middle Aged; Myometrium; Ovary; Pelvis; Prodrugs | 1993 |
Dependence between dissolution rate and porosity of compressed erythromycin acistrate tablets.
Topics: Erythromycin; Kinetics; Microscopy, Electron, Scanning; Molecular Conformation; Molecular Structure; Particle Size; Prodrugs; Solubility; Tablets | 1998 |
The effect of compression force on surface structure, crushing strength, friability and disintegration time of erythromycin acistrate tablets.
Topics: Chemistry, Pharmaceutical; Compressive Strength; Erythromycin; Microscopy, Electron, Scanning; Prodrugs; Surface Properties; Tablets | 1998 |
[Prodrugs].
Topics: Acyclovir; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Epinephrine; Erythromycin; Finland; Humans; Penicillins; Prodrugs; Technology, Pharmaceutical; Valacyclovir; Valine | 1997 |
Effect of compression force on the crystal properties of erythromycin acistrate tablets.
Topics: Chemistry, Pharmaceutical; Compressive Strength; Crystallization; Erythromycin; Microscopy, Electron, Scanning; Particle Size; Powders; Prodrugs; Tablets; X-Ray Diffraction | 2000 |